Support for drug discovery activities

Get support from technology which will enable you to address the challenges associated with heterogeneous isoforms observed when performing stochastic conjugation. Our GS® site-specific conjugation constant region vector technology will help you upgrade your process definition and sample preparation, and move from first generation stochastic conjugation to site-specific conjugation.

From antibody design to sample panel preparation

Experience with a wide range of bioconjugation technologies allows us to help you perform the cell line construction/strain development, GMP cell banking for your antibody along with the payload and linker manufacturing. This experience also allows us to support you with:

  • Preparing an ADC sample panel for your drug discovery activities
  • Perform in silico and cell based immunogenicity testing on naked antibodies
  • Testing the naked mAb for aggregation propensity and re-engineer your mAb for site selective conjugation and reduced aggregation

We will help deliver your product quickly and efficiently for preclinical studies. The streamlined ADC Easy Access program can offer:

  • Preparation of ADC sample panels using a variety of client specified drug-linkers
  • Lab facilities and equipment for milligram-and gram-scale experiments
  • Ability to address various R&D phases based on customer needs
As the industry moves from first generation stochastic conjugation to site-specific conjugation technology, Lonza has developed its own GS® site-specific conjugation constant region vectors. This technology addresses the challenges associated with heterogeneous isoforms observed when performing stochastic conjugation. We have the knowledge in antibody engineering to help find the best possible solution for your program.

Related Content


Our GS Gene Expression System® has options to engineer and express conjugation-competent antibodies. Applications include antibody drug conjugates (ADCs), half-life extension and imaging.

Unlike other contract development and manufacturing organizations (CDMOs), we are in the unique position to offer complete development and manufacturing services from both mammalian cell culture and advanced chemical synthesis for the production of Antibody-Drug Conjugates (ADCs). From process development to manufacturing scale-up, we are proud to offer more ways than ever to deliver your product.

We have 10 years in ADC development and manufacture.